Back to top

Erasca (ERAS) Gains FDA Clearance for Innovative KRAS Inhibitor | ERAS Stock News

Erasca (ERAS) Gains FDA Clearance for Innovative KRAS Inhibitor | ERAS Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Erasca, Inc. (ERAS)